Guardant Health, Inc. (GH): Price and Financial Metrics


Guardant Health, Inc. (GH): $44.41

-1.84 (-3.98%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

GH POWR Grades


  • GH scores best on the Sentiment dimension, with a Sentiment rank ahead of 91.36% of US stocks.
  • GH's strongest trending metric is Quality; it's been moving down over the last 179 days.
  • GH ranks lowest in Momentum; there it ranks in the 5th percentile.

GH Stock Summary

  • Guardant Health Inc's stock had its IPO on October 4, 2018, making it an older stock than merely 11.36% of US equities in our set.
  • With a price/sales ratio of 18.4, Guardant Health Inc has a higher such ratio than 92.31% of stocks in our set.
  • With a year-over-year growth in debt of 60.51%, Guardant Health Inc's debt growth rate surpasses 85.42% of about US stocks.
  • Stocks that are quantitatively similar to GH, based on their financial statements, market capitalization, and price volatility, are BFLY, AYRO, ARLO, RAMP, and IMCR.
  • Visit GH's SEC page to see the company's official filings. To visit the company's web site, go to guardanthealth.com.

GH Valuation Summary

  • GH's price/sales ratio is 39.8; this is 250.66% higher than that of the median Healthcare stock.
  • GH's price/earnings ratio has moved down 3.8 over the prior 35 months.
  • Over the past 35 months, GH's price/sales ratio has gone down 14.2.

Below are key valuation metrics over time for GH.

Stock Date P/S P/B P/E EV/EBIT
GH 2021-08-31 39.8 16.4 -34.0 -35.7
GH 2021-08-30 39.5 16.2 -33.8 -35.5
GH 2021-08-27 37.7 15.5 -32.2 -33.9
GH 2021-08-26 36.9 15.1 -31.5 -33.2
GH 2021-08-25 36.8 15.1 -31.5 -33.1
GH 2021-08-24 35.6 14.6 -30.4 -32.0

GH's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • GH has a Quality Grade of C, ranking ahead of 48.47% of graded US stocks.
  • GH's asset turnover comes in at 0.158 -- ranking 71st of 81 Healthcare stocks.
  • 500 - Internal server error

The table below shows GH's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.158 0.665 -0.174
2021-03-31 0.166 0.662 -0.187
2020-12-31 0.199 0.677 -0.197
2020-09-30 0.244 0.683 -0.205
2020-06-30 0.249 0.677 -0.147
2020-03-31 0.258 0.683 -0.108

GH Price Target

For more insight on analysts targets of GH, see our GH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $167.39 Average Broker Recommendation 1.27 (Strong Buy)

GH Stock Price Chart Interactive Chart >

Price chart for GH

GH Price/Volume Stats

Current price $44.41 52-week high $133.82
Prev. close $46.25 52-week low $27.65
Day low $43.43 Volume 1,159,600
Day high $46.47 Avg. volume 1,337,473
50-day MA $45.75 Dividend yield N/A
200-day MA $78.61 Market Cap 4.53B

Guardant Health, Inc. (GH) Company Bio


Guardant Health, Inc., a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA. The company also provides LUNAR-1 for recurrence detection in cancer survivors; and LUNAR-2 for early detection of cancer in higher risk individuals. Guardant Health, Inc. was founded in 2011 and is based in Redwood City, California.


GH Latest News Stream


Event/Time News Detail
Loading, please wait...

GH Latest Social Stream


Loading social stream, please wait...

View Full GH Social Stream

Latest GH News From Around the Web

Below are the latest news stories about Guardant Health Inc that investors may wish to consider to help them evaluate GH as an investment opportunity.

Guardant Health, Inc. 2021 Q4 - Results - Earnings Call Presentation

No summary available.

Seeking Alpha | February 24, 2022

Why Guardant Health Stock Zoomed 10% Higher Today

It was all about the earnings for the cancer-diagnostics specialist.

The Motley Fool | February 24, 2022

Guardant Health Non-GAAP EPS of -$0.69 beats by $0.39, revenue of $108.11M beats by $9.39M

Guardant Health press release (NASDAQ:GH): Q4 Non-GAAP EPS of -$0.69 beats by $0.39. Revenue of $108.11M (+38.0% Y/Y) beats by $9.39M. Adjusted EBITDA loss was $64.6 million for the fourth quarter of 2021, as compared to a $29.7 million loss Y/Y. Guardant Health expects full year 2022 revenue to be...

Seeking Alpha | February 23, 2022

Guardant Health Reports Fourth Quarter 2021 Financial Results and Provides 2022 Outlook

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter and year ended December 31, 2021. Recent Highlights Revenue of $108 million for the fourth quarter of 2021 and $374 million for the full year 2021, an increase of 38% and 30% over the corresponding period of 2020 Repor

Business Wire | February 23, 2022

Guardant Health, Inc. (GH) Q4 2021 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | February 23, 2022

Read More 'GH' Stories Here

GH Price Returns

1-mo 3.28%
3-mo -33.71%
6-mo -55.69%
1-year -64.66%
3-year -48.56%
5-year N/A
YTD -55.60%
2021 -22.39%
2020 64.93%
2019 107.87%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5693 seconds.